Bristol-myers Company Profile

What is the competitive landscape for BRISTOL-MYERS

BRISTOL-MYERS has seven approved drugs.

There are twenty-eight US patents protecting BRISTOL-MYERS drugs.

There are four hundred and thirty-eight patent family members on BRISTOL-MYERS drugs in forty-six countries and fifty-six supplementary protection certificates in eighteen countries.

Summary for Bristol-myers

International Patents:	438
US Patents:	28
Tradenames:	7
Ingredients:	7
NDAs:	7
Patent Litigation for Bristol-myers:	See patent lawsuits for Bristol-myers
PTAB Cases with Bristol-myers as patent owner:	See PTAB cases with Bristol-myers as patent owner

Drugs and US Patents for Bristol-myers

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Bristol-myers	THALOMID	thalidomide	CAPSULE;ORAL	020785-001	Jul 16, 1998		RX	Yes	No
Bristol-myers	COBENFY	trospium chloride; xanomeline tartrate	CAPSULE;ORAL	216158-001	Sep 26, 2024		RX	Yes	No	10,369,144		Y
Bristol-myers	COBENFY	trospium chloride; xanomeline tartrate	CAPSULE;ORAL	216158-002	Sep 26, 2024		RX	Yes	No	10,369,144		Y
Bristol-myers	ABRAXANE	paclitaxel	POWDER;INTRAVENOUS	021660-001	Jan 7, 2005	AB	RX	Yes	Yes	9,511,046*PED				Y
Bristol-myers	COBENFY	trospium chloride; xanomeline tartrate	CAPSULE;ORAL	216158-002	Sep 26, 2024		RX	Yes	No	11,471,413
Bristol-myers Squibb	DAKLINZA	daclatasvir dihydrochloride	TABLET;ORAL	206843-001	Jul 24, 2015		DISCN	Yes	No	8,329,159			Y
Bristol-myers	COBENFY	trospium chloride; xanomeline tartrate	CAPSULE;ORAL	216158-003	Sep 26, 2024		RX	Yes	Yes	10,369,144		Y

Expired US Patents for Bristol-myers

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Bristol-myers	ABRAXANE	paclitaxel	POWDER;INTRAVENOUS	021660-001	Jan 7, 2005	5,439,686
Bristol-myers	THALOMID	thalidomide	CAPSULE;ORAL	020785-003	Jan 17, 2003	7,435,745
Bristol-myers	THALOMID	thalidomide	CAPSULE;ORAL	020785-002	Jan 17, 2003	7,959,566
Bristol-myers	THALOMID	thalidomide	CAPSULE;ORAL	020785-001	Jul 16, 1998	8,626,531
Bristol-myers	THALOMID	thalidomide	CAPSULE;ORAL	020785-001	Jul 16, 1998	8,143,283
Bristol-myers	THALOMID	thalidomide	CAPSULE;ORAL	020785-004	Jan 10, 2007	8,589,188
Bristol-myers	THALOMID	thalidomide	CAPSULE;ORAL	020785-004	Jan 10, 2007	8,315,886

Paragraph IV (Patent) Challenges for BRISTOL-MYERS drugs

Drugname	Dosage	Strength	Tradename	Submissiondate
	Capsules	200 mg		2006-09-25
	For Injection Suspension	100 mg/vial		2015-12-11
	Capsules	50 mg and 100 mg		2006-12-18
	Capsules	150 mg		2014-02-03
	Injection	10 mg/vial		2013-11-05

International Patents for Bristol-myers Drugs

Country	Patent Number	Estimated Expiration
Slovenia	2635282
Lithuania	2943192
Cyprus	1115594
Japan	5926724
New Zealand	595313
Portugal	1853250
Japan	2016014073

Supplementary Protection Certificates for Bristol-myers Drugs

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1951684	301104	Netherlands		PRODUCT NAME: FEDRATINIB, OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN, OF EEN FARMACEUTISCH AANVAARDBAAR HYDRAAT DAARVAN, IN HET BIJZONDER FEDRATINIBDIHYDROCHLORIDEMONOHYDRAAT; REGISTRATION NO/DATE: EU/1/20/1514 20210209
1853250	C300673	Netherlands		PRODUCT NAME: PACLITAXEL, GEFORMULEERD ALS ALBUMINE-GEBONDEN NANODEELTJES; REGISTRATION NO/DATE: EU/1/07/428/001-002 20131220
2049522	1590007-9	Sweden		PRODUCT NAME: DACLATASVIR AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, ESPECIALLY DACLATASVIR DIHYDROCHLORIDE; REG. NO/DATE: EU/1/14/939 20140826
1951684	132021000000053	Italy		PRODUCT NAME: FEDRATINIB, O UN SUO SALE FARMACEUTICAMENTE ACCETTABILE, O UN SUO IDRATO FARMACEUTICAMENTE ACCETTABILE, IN PARTICOLARE FEDRATINIB DICLORIDRATO MONOIDRATO(INREBIC); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/20/1514, 20210209
0688211	C300358	Netherlands		PRODUCT NAME: THALIDOMIDE; REGISTRATION NO/DATE: EU/1/08/443/001 20080416
2049522	122015000009	Germany		PRODUCT NAME: DACLATASVIR UND PHARMAZEUTISCH AKZEPTABLE SALZE DAVON, INSBESONDERE DACLATASVIR DIHYDROCHLORID; REGISTRATION NO/DATE: EU/1/14/939/001-004 20140822
2049522	C02049522/01	Switzerland		ADRESSAENDERUNG

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• Bristol
• Bristol Myers
• Bristol Myers Squibb
• Bristol-myers
• Bristol-myers Squibb

Pharmaceutical Competitive Landscape Analysis: Bristol-Myers Squibb – Market Position, Strengths & Strategic Insights

In the ever-evolving pharmaceutical industry, Bristol-Myers Squibb (BMS) stands as a formidable player, continuously adapting to market dynamics and pushing the boundaries of medical innovation. This comprehensive analysis delves into BMS's market position, strengths, and strategic insights, offering a detailed look at how the company navigates the competitive landscape of the pharmaceutical sector.

BMS's Market Position

Bristol-Myers Squibb has established itself as a leading biopharmaceutical company with a global presence. The company's focus on innovative medicines for serious diseases has solidified its position in key therapeutic areas.

Global Reach and Sales Performance

BMS's worldwide sales from continuing operations have shown consistent growth over the years. In 2017, the company reported sales of $20.8 billion, representing a 7% increase from the previous year[1]. This growth trajectory has continued, with the company posting first quarter revenues of $11.9 billion in 2024, marking a 5% increase year-over-year[7].

The company's global footprint is evident in its sales distribution:

• United States: 55%
• Europe: 24%
• Rest of the World: 18%
• Other: 3%[1]

This diverse geographical presence allows BMS to mitigate risks associated with market-specific challenges and capitalize on growth opportunities across different regions.

Therapeutic Focus Areas

Bristol-Myers Squibb has strategically positioned itself in high-value therapeutic areas, including:

1. Oncology
2. Immunology
3. Cardiovascular diseases
4. Hematology

The company's leadership in immuno-oncology, in particular, has been a significant driver of its market position. BMS's innovative treatments have become standard care in various cancers, cementing its reputation as a pioneer in this field[6].

Strengths and Competitive Advantages

Bristol-Myers Squibb's success in the pharmaceutical industry can be attributed to several key strengths and competitive advantages.

Robust Research and Development

BMS's commitment to innovation is evident in its substantial investment in research and development. In 2017, the company invested $4.8 billion in pharmaceutical R&D, representing 23.1% of its pharmaceutical sales[1]. This significant allocation to R&D has enabled BMS to maintain a strong pipeline of potential new treatments.

"We want to accelerate our pipeline to deliver transformational medicines to patients around the globe. Pairing cutting-edge research and technology with our unmatched understanding of causal human biology, we aim to provide the best outcomes possible for patients today and in the future." - Robert Plenge, Executive Vice President, Chief Research Officer, Head of Research[8]

Diverse Product Portfolio

BMS boasts a diverse portfolio of pharmaceutical products across multiple therapeutic areas. This diversification helps the company mitigate risks associated with patent expirations and market fluctuations. Key revenue-generating products include:

• Opdivo (nivolumab)
• Eliquis (apixaban)
• Revlimid (lenalidomide)[2]

Strategic Acquisitions and Partnerships

Bristol-Myers Squibb has demonstrated a keen eye for strategic acquisitions and partnerships that enhance its market position. Recent notable acquisitions include:

• Mirati Therapeutics (2024): A $4.8 billion deal to strengthen BMS's oncology portfolio[4]
• Karuna Therapeutics (2024): A $14 billion acquisition to expand into the neuroscience space[4]
• RayzeBio (2023): A $4.1 billion purchase to bolster radiopharmaceutical capabilities[4]

These strategic moves have allowed BMS to expand its product pipeline and enter new therapeutic areas, reinforcing its competitive position.

Technological Innovation

BMS is at the forefront of leveraging cutting-edge technologies to accelerate drug discovery and development. The company's focus on artificial intelligence, machine learning, and digital health solutions is driving efficiency and innovation across its operations[8].

Strategic Insights and Future Outlook

As Bristol-Myers Squibb navigates the competitive pharmaceutical landscape, several strategic insights emerge that will shape its future trajectory.

Focus on Precision Medicine

BMS is increasingly emphasizing personalized medicine approaches, leveraging patient data and advanced analytics to develop more targeted therapies. This strategy aligns with broader industry trends and positions the company to meet evolving patient needs more effectively.

Expansion in Emerging Markets

While BMS has a strong presence in established markets like the United States and Europe, there's significant potential for growth in emerging markets. The company's global expansion efforts, particularly in regions like China, present opportunities for revenue growth and market share expansion.

Digital Transformation Initiatives

Bristol-Myers Squibb is embracing digital technologies to enhance every aspect of its operations, from drug discovery to patient engagement. As Greg Meyers, Executive Vice President and Chief Digital & Technology Officer, notes:

"Technology and digital capabilities will transform our ways of working — from how we develop medicines, to how we improve the patient experience, to how we run our core business operations."[8]

This digital-first approach is expected to drive efficiency, accelerate innovation, and improve patient outcomes.

Pipeline Development and New Drug Approvals

BMS's future success heavily relies on its ability to bring new, innovative treatments to market. The company's robust pipeline, particularly in oncology and immunology, positions it well for future growth. Recent approvals, such as Cobenfy for schizophrenia in September 2024, demonstrate BMS's continued ability to bring novel treatments to market[4].

Addressing Patent Expirations

Like many pharmaceutical companies, BMS faces challenges related to patent expirations on key products. The company's strategy to address this includes:

1. Developing new indications for existing drugs
2. Advancing its pipeline of novel therapies
3. Strategic acquisitions to bolster its product portfolio

Navigating Pricing Pressures and Healthcare Reforms

As healthcare systems globally grapple with rising costs, BMS must navigate pricing pressures and potential healthcare reforms. The company's focus on developing high-value, innovative treatments that demonstrate clear clinical benefits will be crucial in justifying pricing and maintaining market access.

Competitive Landscape

Bristol-Myers Squibb operates in a highly competitive industry, facing competition from both established pharmaceutical giants and emerging biotech companies.

Key Competitors

Major competitors in BMS's key therapeutic areas include:

1. Pfizer
2. Merck
3. Johnson & Johnson
4. Roche
5. AstraZeneca

These companies compete with BMS in areas such as oncology, immunology, and cardiovascular diseases.

Competitive Dynamics

The pharmaceutical industry is characterized by intense competition in research and development, patent races, and market share battles. BMS's ability to maintain its competitive edge relies on:

1. Continuous innovation in drug development
2. Strategic partnerships and collaborations
3. Effective commercialization strategies
4. Navigating regulatory landscapes across global markets

Financial Performance and Market Outlook

Bristol-Myers Squibb's financial performance provides insights into its market position and future prospects.

Recent Financial Results

In the fourth quarter of 2024, BMS reported:

• Revenues of $12.3 billion, an 8% increase year-over-year
• Full-year 2024 revenues of $45.0 billion, a 1% increase from 2023[10]

These results demonstrate the company's ability to drive growth despite challenges such as patent expirations and competitive pressures.

Market Capitalization and Stock Performance

As of 2013, BMS had a market capitalization of US$87 billion[4]. While more recent data is not provided in the search results, the company's continued strong financial performance and strategic acquisitions suggest it remains a significant player in the pharmaceutical industry.

Future Growth Projections

Bristol-Myers Squibb's future growth is expected to be driven by:

1. Continued success of key products like Opdivo and Eliquis
2. New product launches from its pipeline
3. Expansion in emerging markets
4. Synergies from recent acquisitions

Challenges and Opportunities

As Bristol-Myers Squibb looks to the future, it faces both challenges and opportunities that will shape its competitive position.

Challenges

1. Patent expirations on key products
2. Intense competition in core therapeutic areas
3. Pricing pressures and healthcare reforms
4. Regulatory hurdles in drug development and approval processes

Opportunities

1. Expansion in emerging markets with growing healthcare needs
2. Advancements in precision medicine and personalized therapies
3. Leveraging digital technologies and AI in drug discovery and development
4. Strategic acquisitions and partnerships to enhance product portfolio and pipeline

Key Takeaways

• Bristol-Myers Squibb maintains a strong market position in key therapeutic areas, particularly oncology and immunology.
• The company's robust R&D investment, diverse product portfolio, and strategic acquisitions are key strengths.
• BMS is leveraging digital technologies and AI to drive innovation across its operations.
• Future growth will be driven by pipeline development, expansion in emerging markets, and strategic acquisitions.
• Challenges include patent expirations and pricing pressures, but opportunities in precision medicine and digital health present avenues for continued success.

FAQs

1. What are Bristol-Myers Squibb's main therapeutic focus areas? Bristol-Myers Squibb primarily focuses on oncology, immunology, cardiovascular diseases, and hematology.

2. How does BMS invest in research and development? BMS invests heavily in R&D, allocating a significant portion of its pharmaceutical sales (23.1% in 2017) to fund innovative research and drug development.

3. What recent acquisitions has Bristol-Myers Squibb made? Recent notable acquisitions include Mirati Therapeutics, Karuna Therapeutics, and RayzeBio, enhancing BMS's capabilities in oncology, neuroscience, and radiopharmaceuticals.

4. How is Bristol-Myers Squibb addressing the challenge of patent expirations? BMS is addressing patent expirations through developing new indications for existing drugs, advancing its pipeline of novel therapies, and making strategic acquisitions.

5. What role does digital technology play in BMS's strategy? Digital technology is central to BMS's strategy, driving innovation in drug discovery, development, and patient engagement, as well as improving operational efficiency across the company.

Sources cited: [1] https://www.bms.com/about-us/our-impact/economic-responsibility/performance.html [2] https://pitchgrade.com/companies/bristol-myers-squibb [3] https://canvasbusinessmodel.com/blogs/competitors/bristol-myers-squibb-competitive-landscape [4] https://en.wikipedia.org/wiki/Bristol_Myers_Squibb [6] https://www.gurufocus.com/news/2483729/beyond-the-balance-sheet-what-swot-reveals-about-bristolmyers-squibb-co-bmy [7] https://news.bms.com/news/details/2024/Bristol-Myers-Squibb-Reports-First-Quarter-Financial-Results-for-2024/default.aspx [8] https://www.bms.com/about-us/our-company/our-technologies.html [10] https://news.bms.com/news/details/2025/Bristol-Myers-Squibb-Reports-Fourth-Quarter-and-Full-Year-Financial-Results-for-2024/default.aspx

Last updated: 2025-02-13